HRP921157A2 - Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy - Google Patents

Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy Download PDF

Info

Publication number: HRP921157A2
Authority: HR; Croatia
Prior art keywords: delivery system; asa; transdermal delivery; acetylsalicylic acid; active substance
Prior art date: 1991-12-20

Application number

HR921157A

Other languages

English (en)

Croatian (hr)

Inventor

Thomas Kissel

Original Assignee

Lohmann Therapie Syst Lts

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-20

Filing date

1992-10-30

Publication date

1994-10-31

1992-10-30 Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts

1994-10-31 Publication of HRP921157A2 publication Critical patent/HRP921157A2/hr

Links

238000002560 therapeutic procedure Methods 0.000 title abstract 2
229940100640 transdermal system Drugs 0.000 title description 4
239000002253 acid Substances 0.000 title description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 57
229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 53
230000002785 anti-thrombosis Effects 0.000 claims abstract description 11
239000003146 anticoagulant agent Substances 0.000 claims abstract description 10
239000011159 matrix material Substances 0.000 claims abstract description 8
239000013543 active substance Substances 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 13
239000012528 membrane Substances 0.000 claims description 10
230000037317 transdermal delivery Effects 0.000 claims description 8
230000035515 penetration Effects 0.000 claims description 6
229920000642 polymer Polymers 0.000 claims description 5
230000001105 regulatory effect Effects 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000004026 adhesive bonding Methods 0.000 claims description 3
239000006071 cream Substances 0.000 claims description 3
230000007246 mechanism Effects 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims 1
230000001681 protective effect Effects 0.000 claims 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 abstract description 15
230000001225 therapeutic effect Effects 0.000 abstract description 3
239000004480 active ingredient Substances 0.000 abstract 1
229920001600 hydrophobic polymer Polymers 0.000 abstract 1
239000010410 layer Substances 0.000 description 13
239000004793 Polystyrene Substances 0.000 description 10
229920006267 polyester film Polymers 0.000 description 7
239000011241 protective layer Substances 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
239000000853 adhesive Substances 0.000 description 5
239000012790 adhesive layer Substances 0.000 description 5
BODMYPYTCKYRSP-UHFFFAOYSA-N 1,1-dioctylcyclohexane Chemical compound CCCCCCCCC1(CCCCCCCC)CCCCC1 BODMYPYTCKYRSP-UHFFFAOYSA-N 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
230000001754 anti-pyretic effect Effects 0.000 description 4
239000002221 antipyretic Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
208000002193 Pain Diseases 0.000 description 3
230000001760 anti-analgesic effect Effects 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
229920001195 polyisoprene Polymers 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
229960004889 salicylic acid Drugs 0.000 description 3
RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000011149 active material Substances 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000011888 foil Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
-1 glycerine ester Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000000203 mixture Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000000047 product Substances 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
229940117958 vinyl acetate Drugs 0.000 description 2
239000004475 Arginine Substances 0.000 description 1
229920004939 Cariflex™ Polymers 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010048620 Intracardiac thrombus Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229960000800 cetrimonium bromide Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000007903 penetration ability Effects 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

HR921157A 1991-12-20 1992-10-30 Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy HRP921157A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4142483		1991-12-20

Publications (1)

Publication Number	Publication Date
HRP921157A2 true HRP921157A2 (en)	1994-10-31

Family

ID=6447817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR921157A HRP921157A2 (en)	1991-12-20	1992-10-30	Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy

Country Status (23)

Country	Link
US (2)	US6264978B1 (fr)
EP (1)	EP0617623B1 (fr)
JP (1)	JP3748270B2 (fr)
KR (2)	KR100267442B1 (fr)
AT (1)	ATE217528T1 (fr)
AU (1)	AU667067B2 (fr)
CA (1)	CA2125662C (fr)
CZ (1)	CZ285190B6 (fr)
DE (2)	DE4241128C2 (fr)
DK (1)	DK0617623T3 (fr)
ES (1)	ES2176197T3 (fr)
FI (1)	FI113838B (fr)
HR (1)	HRP921157A2 (fr)
HU (1)	HU221679B1 (fr)
IL (1)	IL103917A (fr)
NO (1)	NO306599B1 (fr)
NZ (1)	NZ246158A (fr)
PT (1)	PT617623E (fr)
SI (1)	SI9200312A (fr)
SK (1)	SK67094A3 (fr)
WO (1)	WO1993012799A1 (fr)
YU (1)	YU75093A (fr)
ZA (1)	ZA922814B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5240917A (en) *	1991-04-03	1993-08-31	Keimowitz Rudolph M	Suppression of thromboxane levels by percutaneous administration of aspirin
WO1994013302A1 (fr) *	1991-12-20	1994-06-23	Lts Lohmann Therapie-Systeme Gmbh & Co. Kg	Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
US6071896A (en) *	1992-06-16	2000-06-06	Gundersen Clinic, Ltd.	Suppression of thromboxane levels by percutaneous administration of aspirin
SK75495A3 (en) *	1992-12-07	1996-05-08	Lohmann Therapie Syst Lts	Transdermal administration system containing acetylsalicylic acid for antithrombotic therapy and the prophylaxis of cancer
DE4332093C2 (de) *	1993-09-22	1995-07-13	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung
DE4429663C2 (de) *	1994-08-20	1997-09-11	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Hydrolyseschutz
AU6709096A (en) *	1995-07-27	1997-02-26	Cal International Limited	Pharmaceutical preparation for percutaneous absorbtion
WO1997004757A1 (fr) *	1995-07-27	1997-02-13	Cal International Limited	Formulation transdermique a base de nitrate
WO1997004759A1 (fr) *	1995-07-27	1997-02-13	Cal International Limited	Timbre transdermique contenant de l'aspirine
DE69635298T2 (de) *	1995-12-26	2006-07-13	Teikoku Seiyaku K.K.	Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
DE19601487C2 (de) *	1996-01-17	2001-09-13	Micronas Gmbh	Vorrichtung zum Behandeln von malignen Gewebsveränderungen
JPH1112177A (ja) *	1997-06-25	1999-01-19	Teikoku Seiyaku Co Ltd	安定なアスピリン含有外用製剤
DE19949252B4 (de) *	1999-10-13	2004-02-12	Lts Lohmann Therapie-Systeme Ag	Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
JP2001187739A (ja) *	1999-12-28	2001-07-10	Teikoku Seiyaku Co Ltd	アレルギー性皮膚疾患治療用外用剤
RU2201234C2 (ru) *	2000-12-05	2003-03-27	Воронежский государственный университет	Полимерный водорастворимый аналог ацетилсалициловой кислоты и способ его получения
WO2003018023A1 (fr) *	2001-08-23	2003-03-06	Bruce Frome	Compositions et methodes permettant de cibler la circulation cerebrale et de traiter une cephalee
US20040248858A1 (en) *	2003-06-09	2004-12-09	Parghi Kaumil H.	Cure for cancer
US20060127463A1 (en) *	2004-12-15	2006-06-15	Nugara Peter N	Composite structure including a low vinyl acetate layer
US20060188558A1 (en) *	2005-02-18	2006-08-24	Mylan Technologies, Inc.	Transdermal systems having control delivery system
CA2656858C (fr)	2006-07-09	2016-01-19	Techfields Biochem Co. Ltd	Promedicaments hydrosolubles a charge positive de l'acide acetylsalicylique
US20090238763A1 (en) *	2006-07-09	2009-09-24	Chongxi Yu	High penetration compositions and uses thereof
US20090221703A1 (en)	2006-07-09	2009-09-03	Chongxi Yu	High penetration composition and uses thereof
BRPI0810314A2 (pt) *	2007-05-09	2014-10-21	Buckman Labor Inc	"emulsão de colagem de anidrido alquenil succínio, proceso para colar papel, mistura com anidrido alquenil succínico e agente emulsificante"
KR20150058566A (ko)	2007-06-04	2015-05-28	테크필즈 인크	매우 높은 피부 및 막 침투율을 가지는 ｎｓａｉａ 약물전구체 및 이들의 새로운 의약적 용도
BR122021011394B1 (pt)	2008-12-04	2021-09-28	Chongxi Yu	Composição de alta penetração de um fármaco principal, e uso de uma hpc
WO2011076401A1 (fr)	2009-12-23	2011-06-30	Holger Schankin	Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique
CN111012914A (zh)	2012-01-18	2020-04-17	苏州泰飞尔医药有限公司	治疗肺部疾病的高穿透力前药组合物和医药组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3598122A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) *	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en) *	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
FR2297612A1 (fr)	1975-01-20	1976-08-13	Moorleghem Guy Van	Procede de fabrication d'un produit analgesique a usage externe
US4012508A (en)	1975-02-03	1977-03-15	Burton Verna M	Topical composition and method
US4219548A (en)	1978-09-01	1980-08-26	The Procter & Gamble Company	Topical anti-inflammatory composition
FR2496459A1 (fr)	1980-12-19	1982-06-25	Astier Laboratoires Docteur P	Composition pharmaceutique sous forme d'un gel contenant de l'acide acetylsalicylique
US4460368A (en) *	1981-10-29	1984-07-17	Almedco, Inc.	Trans-dermal medication system
IL68965A (en)	1983-06-13	1987-02-27	Rafa Labor Ltd	Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders
US4640689A (en) *	1983-08-18	1987-02-03	Drug Delivery Systems Inc.	Transdermal drug applicator and electrodes therefor
DE3583698D1 (de)	1984-04-23	1991-09-12	Kao Corp	Perkutaner absorptions-beschleuniger und diesen enthaltendes praeparat.
JPS61167615A (ja)	1985-01-18	1986-07-29	Teisan Seiyaku Kk	薬剤投与方法
US4810699A (en)	1987-02-20	1989-03-07	American Home Products Corporation	Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
JPH01203336A (ja)	1988-02-09	1989-08-16	Teikoku Seiyaku Kk	経皮・口腔粘膜適用製剤
JPH01242521A (ja)	1988-03-23	1989-09-27	Nikko Kemikaruzu Kk	経皮吸収性を高めた消炎鎮痛薬組成物
US4975269A (en)	1989-07-31	1990-12-04	Leonard Chavkin	Shelf stable aspirin solutions
DK0578780T3 (da)	1991-04-03	2003-08-18	Univ Vanderbilt	Sænkning af thromboxanniveauer ved perkutan indgivelse af aspirin

1992
- 1992-10-30 HR HR921157A patent/HRP921157A2/hr not_active Application Discontinuation
- 1992-11-10 SI SI19929200312A patent/SI9200312A/sl unknown
- 1992-11-29 IL IL10391792A patent/IL103917A/en not_active IP Right Cessation
- 1992-12-07 DE DE4241128A patent/DE4241128C2/de not_active Expired - Fee Related
- 1992-12-16 HU HU9401849A patent/HU221679B1/hu not_active IP Right Cessation
- 1992-12-16 ES ES93900057T patent/ES2176197T3/es not_active Expired - Lifetime
- 1992-12-16 SK SK670-94A patent/SK67094A3/sk unknown
- 1992-12-16 PT PT93900057T patent/PT617623E/pt unknown
- 1992-12-16 CZ CZ941456A patent/CZ285190B6/cs not_active IP Right Cessation
- 1992-12-16 DK DK93900057T patent/DK0617623T3/da active
- 1992-12-16 AU AU31589/93A patent/AU667067B2/en not_active Ceased
- 1992-12-16 US US08/256,065 patent/US6264978B1/en not_active Expired - Fee Related
- 1992-12-16 EP EP93900057A patent/EP0617623B1/fr not_active Expired - Lifetime
- 1992-12-16 CA CA002125662A patent/CA2125662C/fr not_active Expired - Fee Related
- 1992-12-16 KR KR1019940702176A patent/KR100267442B1/ko not_active Expired - Fee Related
- 1992-12-16 WO PCT/EP1992/002914 patent/WO1993012799A1/fr not_active Ceased
- 1992-12-16 AT AT93900057T patent/ATE217528T1/de not_active IP Right Cessation
- 1992-12-16 NZ NZ246158A patent/NZ246158A/en unknown
- 1992-12-16 JP JP51140593A patent/JP3748270B2/ja not_active Expired - Fee Related
- 1992-12-16 DE DE59209956T patent/DE59209956D1/de not_active Expired - Fee Related
- 1992-12-18 ZA ZA922814A patent/ZA922814B/xx unknown
1993
- 1993-11-18 KR KR1019950702301A patent/KR100267359B1/ko not_active Expired - Fee Related
- 1993-12-02 YU YU75093A patent/YU75093A/sh unknown
1994
- 1994-03-22 US US08/216,089 patent/US5861170A/en not_active Expired - Lifetime
- 1994-06-17 FI FI942922A patent/FI113838B/fi active
- 1994-06-17 NO NO942325A patent/NO306599B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ246158A (en)	1995-10-26
IL103917A (en)	1996-09-12
NO306599B1 (no)	1999-11-29
SK67094A3 (en)	1995-03-08
YU75093A (sh)	1997-08-22
KR100267442B1 (ko)	2000-11-01
JPH07502521A (ja)	1995-03-16
DE4241128A1 (en)	1993-06-24
HU221679B1 (hu)	2002-12-28
JP3748270B2 (ja)	2006-02-22
DE59209956D1 (de)	2002-06-20
FI942922A0 (fi)	1994-06-17
US5861170A (en)	1999-01-19
KR950703972A (ko)	1995-11-17
ATE217528T1 (de)	2002-06-15
CA2125662C (fr)	2006-10-17
PT617623E (pt)	2002-10-31
FI113838B (fi)	2004-06-30
CA2125662A1 (fr)	1993-07-08
ES2176197T3 (es)	2002-12-01
SI9200312A (en)	1993-06-30
CZ145694A3 (en)	1995-01-18
DE4241128C2 (de)	1996-05-23
IL103917A0 (en)	1993-04-04
FI942922L (fi)	1994-06-17
CZ285190B6 (cs)	1999-06-16
US6264978B1 (en)	2001-07-24
EP0617623A1 (fr)	1994-10-05
AU3158993A (en)	1993-07-28
HUT74559A (en)	1997-01-28
WO1993012799A1 (fr)	1993-07-08
HU9401849D0 (en)	1994-09-28
DK0617623T3 (da)	2002-09-09
NO942325L (no)	1994-06-17
ZA922814B (en)	1993-06-23
EP0617623B1 (fr)	2002-05-15
NO942325D0 (no)	1994-06-17
AU667067B2 (en)	1996-03-07
KR100267359B1 (ko)	2000-11-01

Legal Events

Date	Code	Title	Description
1994-10-31	A1OB	Publication of a patent application
1995-05-02	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2001-10-30	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20011030 Year of fee payment: 10
2003-10-22	ODBI	Application refused

Publication	Publication Date	Title
HRP921157A2 (en)	1994-10-31	Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
JP2604097B2 (ja)	1997-04-23	皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム
JPH0442025B2 (fr)	1992-07-10
CA2371064A1 (fr)	2000-11-02	Procedes d'administration de cetyl myristoleate
US6716877B2 (en)	2004-04-06	Method to treat chronic heart failure and/or elevated cholesterol levels
CA1309661C (fr)	1992-11-03	Systeme d'administration transdermiques
WO1999062557A1 (fr)	1999-12-09	Composition destinee a une administration transdermique de medicaments anti-inflammatoires non steroidiens
FI120719B (fi)	2010-02-15	Menetelmä asetyylisalisyylihappoa sisältävän transdermaalisen järjestelmän valmistamiseksi
JP2000515868A (ja)	2000-11-28	痴呆の治療および／または予防用製剤
US5965155A (en)	1999-10-12	Transdermal therapeutic system with pentylene tetrazol as active substance
CA3154122C (fr)	2025-07-08	Réduction de temps de décalage et/ou de pulvérisation de glace
SI9400023A (sl)	1995-08-31	Transdermalni sistem dajanja, vsebujoč acetilsalicilno kislino za antitrombotsko terapijo in profilakso proti raku
CN111991371B (zh)	2023-02-03	一种gsh浓度响应性治疗甲状腺功能亢进的药质体水凝胶贴剂及其制备方法
KR0167583B1 (ko)	1999-01-15	경피투약을 위한 조성물 및 적층복합체
KR19980027318A (ko)	1998-07-15	비스테로이드성 소염진통제를 함유하는 경피흡수제제와 그의 제조방법
WO1994013302A1 (fr)	1994-06-23	Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer